Stay updated on Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial page.

Latest updates to the Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial page
- CheckyesterdayChange DetectedAdministrative update to the study record reflecting a new last update date; no changes to the interventions, eligibility criteria, primary or secondary outcomes, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check9 days agoNo Change Detected
- Check30 days agoChange DetectedMajor update: announces a version upgrade to v3.2.0 and publicly states funding-related operational notices, including that transactions may not be processed until appropriations are enacted.SummaryDifference2%

- Check37 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.0%

- Check52 days agoChange DetectedThe page revision updated from v3.0.1 to v3.0.2, and the 'Back to Top' element was removed.SummaryDifference0.1%

- Check59 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.SummaryDifference0.1%

- Check66 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location, as well as comprehensive drug information for various medications related to cancer treatment. Notably, the previous version's details on certain drugs and related topics have been removed.SummaryDifference4%

Stay in the know with updates to Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial page.